Robert Hillman

CeleCor Therapeutics, Inc. engages in the development of RUC-4, a novel small molecule platelet inhibitor of the platelet aIIbß3 receptor. Its product is design to administered subcutaneously via auto-injector to facilitate its use as the first point of medical contact in order to improve the treatment of serious heart attacks. The company was founded by Barry S. Collein, Robert S. Hillman and Andreas Ritzi and is headquartered in San Diego, CA.

CeleCor Therapeutics, Inc. engages in the development of RUC-4, a novel small molecule platelet inhibitor of the platelet aIIbß3 receptor. Its product is design to administered subcutaneously via auto-injector to facilitate its use as the first point of medical contact in order to improve the treatment of serious heart attacks. The company was founded by Barry S. Collein, Robert S. Hillman and Andreas Ritzi and is headquartered in San Diego, CA.

CeleCor Therapeutics, Inc. engages in the development of RUC-4, a novel small molecule platelet inhibitor of the platelet aIIbß3 receptor. Its product is design to administered subcutaneously via auto-injector to facilitate its use as the first point of medical contact in order to improve the treatment of serious heart attacks. The company was founded by Barry S. Collein, Robert S. Hillman and Andreas Ritzi and is headquartered in San Diego, CA.